Neurogene (NGNE) Accumulated Expenses (2013 - 2026)

Neurogene's Accumulated Expenses history runs 14 years deep, the most recent figure standing at $11.1 million for Q1 2026.

• Quarterly Accumulated Expenses rose 62.56% year-over-year to $11.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (up 62.56% YoY) and the FY2025 annual result came in at $10.8 million, up 10.53% from the prior year.
• Accumulated Expenses was $11.1 million for Q1 2026 at Neurogene, up from $10.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $17.5 million in Q4 2023 and bottomed at $5.3 million in Q4 2022.
• A 5-year average of $9.5 million and a median of $9.4 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 228.61% — and 2024, when it slumped 44.38%.
• Neurogene's Accumulated Expenses stood at $5.3 million in 2022, then jumped by 228.61% to $17.5 million in 2023, then slumped by 44.38% to $9.7 million in 2024, then climbed by 10.53% to $10.8 million in 2025, then gained by 3.51% to $11.1 million in 2026.
• Business Quant data shows NGNE's Accumulated Expenses at $11.1 million in Q1 2026, $10.8 million in Q4 2025, and $9.4 million in Q3 2025.